Accelerometry for remote monitoring of physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study

被引:40
作者
van Eijk, Ruben P. A. [1 ,2 ]
Bakers, Jaap N. E. [3 ]
Bunte, Tommy M. [1 ]
de Fockert, Arianne J. [1 ]
Eijkemans, Marinus J. C. [2 ]
van den Berg, Leonard H. [1 ]
机构
[1] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Biostat & Res Support, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Rehabil, Utrecht, Netherlands
关键词
Amyotrophic lateral sclerosis; Accelerometry; Clinical trial; Longitudinal cohort study; ALS CLINICAL-TRIALS; PROGRESSION; SURVIVAL; TIME;
D O I
10.1007/s00415-019-09427-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The extensive heterogeneity between patients with amyotrophic lateral sclerosis (ALS) complicates the quantification of disease progression. In this study, we determine the value of remote, accelerometer-based monitoring of physical activity in patients with ALS. Methods This longitudinal cohort study was conducted in a home-based setting; all study materials were sent by mail. Patients wore the ActiGraph during waking hours for 7 days every 2-3 months and provided information regarding their daily functioning (ALSFRS-R). We defined four accelerometer-based endpoints that either reflect the average daily activity or quantify the patient's physical capacity. Results A total of 42 patients participated; the total valid monitoring period was 9288 h with a 93.0% adherence rate. At baseline, patients were active 27.9% (range 11.6-52.4%) of their time; this declined by 0.64% (95% 0.43-0.86, p < 0.001) per month. Accelerometer-based endpoints were strongly associated with the ALSFRS-R (r 0.78, 95% CI 0.63-0.92, p < 0.001), but showed less variability over time than the ALSFRS-R (coefficient of variation 0.64-0.81 vs. 1.06, respectively). Accelerometer-based endpoints could reduce sample size by 30.3% for 12-month trials and 44.6% for 18-month trials; for trials lasting less than 9 months, the ALSFRS-R resulted in smaller sample sizes. Conclusion Accelerometry is an objective method for quantifying disease progression, which could obtain real-world insights in the patient's physical functioning and may personalize the delivery of care. In addition, remote monitoring provides patients with the opportunity to participate in clinical trials from home, paving the way to a patient-centric clinical trial model.
引用
收藏
页码:2387 / 2395
页数:9
相关论文
共 50 条
  • [31] Clinical Determinants of Disease Progression in Amyotrophic Lateral Sclerosis-A Retrospective Cohort Study
    Requardt, Maria Viktoria
    Gorlich, Dennis
    Grehl, Torsten
    Boentert, Matthias
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [32] Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort
    Kacem, Imen
    Sghaier, Ikram
    Bougatef, Sabrine
    Nasri, Amina
    Gargouri, Amina
    Ajroud-Driss, Senda
    Gouider, Riadh
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2020, 21 (1-2) : 131 - 139
  • [33] Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population-Based Cohort Study
    Vaage, Anders Myhre
    Holmoy, Trygve
    Dahl, Jesper
    Stigum, Hein
    Meyer, Haakon E.
    Nakken, Ola
    EUROPEAN JOURNAL OF NEUROLOGY, 2025, 32 (03)
  • [34] Minocycline in amyotrophic lateral sclerosis: a pilot study
    F. E. Pontieri
    A. Ricci
    C. Pellicano
    D. Benincasa
    F. R. Buttarelli
    Neurological Sciences, 2005, 26 : 285 - 287
  • [35] Minocycline in amyotrophic lateral sclerosis: a pilot study
    Pontieri, FE
    Ricci, A
    Pellicano, C
    Benincasa, D
    Buttarelli, FR
    NEUROLOGICAL SCIENCES, 2005, 26 (04) : 285 - 287
  • [36] Early-Onset Alopecia and Amyotrophic Lateral Sclerosis: A Cohort Study
    Fondell, Elinor
    Fitzgerald, Kathryn C.
    Falcone, Guido J.
    O'Reilly, Eilis J.
    Ascherio, Alberto
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2013, 178 (07) : 1146 - 1149
  • [37] Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study
    Tseng, Chia-Chun
    Chang, Shun-Jen
    Tsai, Wen-Chan
    Ou, Tsan-Teng
    Wu, Cheng-Chin
    Sung, Wan-Yu
    Hsieh, Ming-Chia
    Yen, Jeng-Hsien
    ARTHRITIS CARE & RESEARCH, 2017, 69 (08) : 1231 - 1237
  • [38] Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study
    Zucchi, Elisabetta
    Musazzi, Umberto Maria
    Fedele, Guido
    Martinelli, Ilaria
    Gianferrari, Giulia
    Simonini, Cecilia
    Fini, Nicola
    Ghezzi, Andrea
    Caputo, Maria
    Sette, Elisabetta
    Vacchiano, Veria
    Zinno, Lucia
    Anceschi, Pietro
    Canali, Elena
    Vinceti, Marco
    Ferro, Salvatore
    Mandrioli, Jessica
    ECLINICALMEDICINE, 2023, 65
  • [39] The Use of Antidepressant Medication before and after the Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Cohort Study
    Pisa, Federica Edith
    Logroscino, Giancarlo
    Casetta, Anica
    Cecotti, Laura
    Verriello, Lorenzo
    Bratina, Alessio
    Sartori, Arianna
    de Lorenzo, Lucio Lazzarino
    Eleopra, Roberto
    Barbone, Fabio
    NEUROEPIDEMIOLOGY, 2015, 44 (02) : 91 - 98
  • [40] Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
    Anne-Lene Kjældgaard
    Katrine Pilely
    Karsten Skovgaard Olsen
    Anders Hedegaard Jessen
    Anne Øberg Lauritsen
    Stephen Wørlich Pedersen
    Kirsten Svenstrup
    Merete Karlsborg
    Helle Thagesen
    Morten Blaabjerg
    Ásta Theódórsdóttir
    Elisabeth Gundtoft Elmo
    Anette Torvin Møller
    Lone Bonefeld
    Mia Berg
    Peter Garred
    Kirsten Møller
    BMC Neurology, 21